NCT04335292 - Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Osimertinib First-Line

Osimertinib, 80 mg, oral, daily

DRUG

Platinum + Pemetrexed Chemotherapy Second-Line

Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.

DRUG

Osimertinib Third-Line

Rechallenge with osimertinib, 80 mg, oral, daily

Trial Locations (10)

V5Z 4E6

RECRUITING

BC Cancer Agency, Vancouver

V7L 2L7

RECRUITING

Lions Gate Hospital, Vancouver

L6R 3J7

RECRUITING

William Osler Health System, Brampton

L8V 5C2

RECRUITING

Hamilton Health Sciences Centre, Juravinski Cancer Centre, Hamilton

N2G 1G3

RECRUITING

Grand River Regional Cancer Centre, Kitchener

N6A 5W9

RECRUITING

London Regional Cancer Program of the Lawson Health Research Institute, London

L1G 2B9

RECRUITING

Durham Regional Cancer Centre, Lakeridge Health, Oshawa

K1H 8L6

RECRUITING

The Ottawa Hospital, Ottawa

M4N 3M5

RECRUITING

Sunnybrook Research Institute, Toronto

M5G 2M9

RECRUITING

Princess Margaret Hospital, Toronto